Equities research analysts expect Humana Inc. (NYSE:HUM) to report $3.23 earnings per share for the current quarter, according to Zacks. Seven analysts have made estimates for Humana’s earnings, with the highest EPS estimate coming in at $3.32 and the lowest estimate coming in at $3.10. Humana reported earnings per share of $3.18 during the same quarter last year, which suggests a positive year over year growth rate of 1.6%. The business is scheduled to issue its next quarterly earnings results on Friday, November 3rd.

According to Zacks, analysts expect that Humana will report full year earnings of $11.54 per share for the current financial year, with EPS estimates ranging from $11.47 to $11.63. For the next year, analysts expect that the company will post earnings of $12.25 per share, with EPS estimates ranging from $11.95 to $12.92. Zacks’ earnings per share averages are an average based on a survey of research analysts that that provide coverage for Humana.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, August 2nd. The insurance provider reported $3.49 EPS for the quarter, beating the Zacks’ consensus estimate of $3.08 by $0.41. Humana had a return on equity of 15.85% and a net margin of 3.37%. The firm had revenue of $13.53 billion during the quarter, compared to analysts’ expectations of $13.61 billion. During the same quarter last year, the firm posted $2.30 earnings per share.

Several research analysts have recently issued reports on the company. Zacks Investment Research raised Humana from a “hold” rating to a “buy” rating and set a $255.00 target price for the company in a research report on Tuesday, June 13th. BidaskClub lowered Humana from a “buy” rating to a “hold” rating in a research report on Tuesday, June 13th. Citigroup Inc. assumed coverage on Humana in a research report on Wednesday, June 28th. They issued a “buy” rating and a $275.00 target price for the company. Credit Suisse Group reissued an “outperform” rating and issued a $260.00 target price (up previously from $250.00) on shares of Humana in a research report on Thursday, August 3rd. Finally, Deutsche Bank AG increased their target price on Humana from $234.00 to $243.00 and gave the stock a “hold” rating in a research report on Monday, August 7th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and thirteen have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $244.35.

In other Humana news, insider Elizabeth D. Bierbower sold 9,786 shares of the firm’s stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $259.00, for a total transaction of $2,534,574.00. Following the sale, the insider now directly owns 18,042 shares of the company’s stock, valued at $4,672,878. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider William Kevin Fleming sold 3,071 shares of the firm’s stock in a transaction dated Wednesday, August 23rd. The shares were sold at an average price of $250.98, for a total value of $770,759.58. Following the sale, the insider now directly owns 7,681 shares in the company, valued at $1,927,777.38. The disclosure for this sale can be found here. Over the last three months, insiders have sold 60,566 shares of company stock worth $15,326,746. Insiders own 0.80% of the company’s stock.

A number of large investors have recently bought and sold shares of the business. Achmea Investment Management B.V. raised its holdings in Humana by 25.3% during the second quarter. Achmea Investment Management B.V. now owns 12,637 shares of the insurance provider’s stock valued at $3,039,000 after acquiring an additional 2,551 shares during the period. WFG Advisors LP raised its holdings in Humana by 4.5% during the second quarter. WFG Advisors LP now owns 469 shares of the insurance provider’s stock valued at $113,000 after acquiring an additional 20 shares during the period. Toronto Dominion Bank raised its holdings in Humana by 21.5% during the second quarter. Toronto Dominion Bank now owns 48,951 shares of the insurance provider’s stock valued at $11,776,000 after acquiring an additional 8,657 shares during the period. Dynamic Technology Lab Private Ltd bought a new stake in Humana during the second quarter valued at about $790,000. Finally, Colony Group LLC bought a new stake in Humana during the second quarter valued at about $225,000. 95.14% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Humana Inc. (HUM) Expected to Post Earnings of $3.23 Per Share” was reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another publication, it was copied illegally and republished in violation of international copyright law. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/09/08/humana-inc-hum-expected-to-post-earnings-of-3-23-per-share.html.

Shares of Humana (HUM) opened at 256.53 on Friday. The firm has a market cap of $37.07 billion, a PE ratio of 21.10 and a beta of 0.87. The firm has a 50-day moving average price of $247.05 and a 200-day moving average price of $229.66. Humana has a 52 week low of $163.50 and a 52 week high of $259.47.

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 27th. Shareholders of record on Tuesday, August 29th will be issued a dividend of $0.40 per share. The ex-dividend date of this dividend is Thursday, September 28th. This represents a $1.60 dividend on an annualized basis and a yield of 0.62%. Humana’s dividend payout ratio is presently 13.06%.

Humana Company Profile

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Get a free copy of the Zacks research report on Humana (HUM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Humana (NYSE:HUM)

Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with MarketBeat.com's FREE daily email newsletter.